PMV Pharmaceuticals Inc. 2026年季度报告

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of As of May 12, 2026, the registrant had 53,331,766 shares of common stock, $0.00001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATION Item 1.Condensed Consolidated Financial Statements (Unaudited)Condensed Consolidated Balance Sheets (Unaudited)Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)Condensed Consolidated Statements of Cash Flows (Unaudited)Notes to Unaudited Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and ProceduresPART II.OTHER INFORMATIONItem 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. We make suchforward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and otherfederal securities laws. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q,including statements regarding our future results of operations and financial position, business strategy, development plans, planned In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,”“plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or“continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly •our financial performance; •the sufficiency of our existing cash, cash equivalents, and marketable securities to fund our future operating expenses andcapital expenditure requirements;•our need to raise additional funding before we can expect to generate any revenues from product sales;•our ability to obtain additional funding for our operations, when needed, including funding necessary to complete furtherdevelopment and commercialization of our product candidates, if approved;•the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;•our anticipated use of our existing cash, cash equivalents, and marketable securities and any proceeds from the ATMProgram (as defined below);•the implementation of our strategic plans for our business and product candidates;•the size of the market opportunity for our product candidates and our ability to maximize those opportunities;•the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trialsand investigational new drug applications, or IND, and other regulatory submissions;•the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates;•our estimates of the number of patients for each of our programs including patients expected to have certain p53mutations and the number of patients that will enroll in our clinical trials;•the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other favorable results;•our plans relating to the clinical development of our product candidates, including the disease areas to be eval